In the first comprehensive analysis of clinical trial enrollment among older adults with blood cancers, researchers from the US FDA found significant gaps in participation among those aged 75 and older when considered against the incidence of these malignancies in this age group, according to research being presented today during the 59th ASH Annual Meeting and Exposition in Atlanta.
High-intensity exercise three times a week is safe for individuals with early-stage Parkinson's disease and decreases worsening of motor symptoms, according to a new phase 2, multi-site trial led by University of Colorado Anschutz Medical Campus and Northwestern Medicine scientists.
Researchers have presented the association between tumor response and health-related quality of life in patients with metastatic Merkel cell carcinoma treated with avelumab.
As previously informed, the Phase III trial, ADMYRE, which compared plitidepsin in combination with dexamethasone versus dexamethasone alone met its primary endpoint, progression free survival, and secondary objectives, overall survival and safety
Preliminary findings indicate gene therapy pioneered at St. Jude Children's Research Hospital is safe and effective for babies with a devastating inherited disorder that leaves them with little or no immune protection.
Immunotherapy agents known as checkpoint inhibitors have shown considerable promise in patients with hematologic cancers who relapse after a transplant with donor stem cells. Preliminary results from the first clinical trial in these patients of one such agent -- nivolumab -- indicate that along with signs of effectiveness, it also produced significant side effects at the dose initially studied. The findings indicate a need for further clinical trials in this group before being considered for off-label use with these patients, Dana-Farber Cancer Institute investigators report.
Results from a phase 2 clinical trial, presented by Seattle Children's Research Institute at the 59th American Society of Hematology (ASH) Annual Meeting, show that the drug Abatacept (Orencia) nearly eliminated life-threatening severe acute graft-versus-host disease (GvHD) in patients receiving hematopoietic stem cell transplants.
Intensive surveillance including a dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) exam every six months was far more effective in detecting breast cancer in younger women with a high-risk genetic profile than an annual mammogram. DCE-MRI every six months performed well for early detection of invasive breast cancer in high-risk women.
Late recurrence five+ years after surgery accounts for at least half of all breast cancer recurrences. There are no tests that identify who is at highest risk. ECOG-ACRIN Cancer Research Group researchers studied a blood test for circulating tumor cells, finding that in women cancer-free five after diagnosis, 5% had a positive test, which was associated with a 35% recurrence risk after two years, compared with only 2% with a negative test. Findings require follow-up.
Researchers have discovered a mechanism of resistance to checkpoint inhibitors and how to reverse it. The biomarker results from the IMvigor210 study are reported at the ESMO Immuno Oncology Congress 2017.